Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

11 results
Display

Treatment of chronic fibrosing interstitial lung diseases

Lee J

Interstitial lung diseases (ILD) refers to a large and heterogenous group of parenchymal lung disorders. It is difficult to diagnose and classify ILD. Nevertheless, accurate diagnosis of ILD is crucial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current and future treatment for idiopathic pulmonary fibrosis

Choi WI

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fibrosing interstitial lung disease, which is associated with a short survival rate. The decline in forced vital capacity in patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions

Choi WI

Idiopathic pulmonary fibrosis (IPF) was considered untreatable until the development of therapeutic drugs and diagnostic technology that made it possible to slow the progression of IPF. In 2014, pirfenidone and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combination Therapy With Polydeoxyribonucleotide and Pirfenidone Alleviates Symptoms of Acute Respiratory Distress Syndrome in Human Lung Epithelial A549 Cells

Hwang JJ, Ko IG, Jin JJ, Hwang L, Kim SH, Jeon JW, Paik SS, Chang BS, Choi CW

Purpose: Acute respiratory distress syndrome (ARDS) is characterized by its acute onset of symptoms such as bilateral pulmonary infiltrates, severe hypoxemia, and pulmonary edema. Many patients with ARDS survive in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Diagnosis and Management of Hypersensitivity Pneumonitis

Leone PM, Richeldi L

Hypersensitivity Pneumonitis (HP) one of the most common interstitial lung diseases (ILDs) is characterized by exposure to an inhaled inciting antigen that leads to a host immunologic reaction determining interstitial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacological treatment of pulmonary fibrosis

Choi WI

Idiopathic pulmonary fibrosis (IPF) is a condition that has been described as alveolar collapse and thickening, which correlate with dysregulated surfactant production and injury to type 2 alveolar cells. As...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human Adipose-derived Mesenchymal Stem Cells Attenuate Early Stage of Bleomycin Induced Pulmonary Fibrosis: Comparison with Pirfenidone

Reddy M, Fonseca L, Gowda S, Chougule B, Hari A, Totey S

BACKGROUND AND OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, invariably fatal fibrotic lung disease with no lasting option for therapy. Mesenchymal stem cells (MSCs) could be a promising...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cytotoxicities and Anti-Fibrotic Effects of Pirfenidone and Mitomycin C on Human Fibroblasts

Park KS, Hong SM, Iizuka Y, Kim CY, Seong GJ

  • KMID: 2338815
  • J Korean Ophthalmol Soc.
  • 2014 Jul;55(7):1077-1083.
PURPOSE: The cytotoxicities and anti-fibrotic effects of mitomycin C and pirfenidone on human dermal fibroblast were evaluated. METHODS: Initially, 24-hour cell cultures were exposed to transforming growth factor (TGF)-beta1, different concentrations...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Interstitial Lung Disease

Chung MP

  • KMID: 2319549
  • Tuberc Respir Dis.
  • 2011 Sep;71(3):163-171.
Recently published articles on interstitial lung disease (ILD) have focused on the accurate diagnosis of idiopathic pulmonary fibrosis (IPF), serum biomarkers, acute exacerbation of IPF, the prognostic factors of ILD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pirfenidone Suppressed the Development of Glomerulosclerosis in the FGS/Kist mouse

Park HS, Bao L, Kim YJ, Cho IH, Lee CH, Hyun BH, Margolin S, Park YH

Pirfenidone(PFD) is a newly developed anti-fibrotic agent. We evaluated the effect of PFD for the prevention of renal fibrosis using a spontaneous progressive glomerulosclerosis animal model, FGS/Kist mice. Male and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pirfenidone Treatment During Peritoneal Dialysis Reduces Peritoneal Fibrosis in Rats

Lee CH, Kim ES, Lee JH

  • KMID: 1610176
  • Korean J Nephrol.
  • 2003 Jul;22(4):374-381.
BACKGROUND: Peritoneal fibrosis is one of the most serious complications in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). In order to determine the effects of pirfenidone treatment for reducing peritoneal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr